In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine

Diabetic Medicine

Volumn 25, Issue 3, 2008, Pages 326-332

  Bruttomesso, D ^a,f   Crazzolara, D ^a   Maran, A ^a   Costa, S ^a   Dal Pos, M ^a   Girelli, A ^b   Lepore, G ^c   Aragona, M ^d   Iori, E ^a   Valentini, U ^b   Del Prato, S ^d   Tiengo, A ^a   Buhr, A ^e   Trevisan, R ^c   Baritussio, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Diabetologic Unit   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e Disetronic Medical Systems AG   (Switzerland)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Continuous subcutaneous insulin infusion; Glucose variability; Multiple daily injections with glargine; Treatment satisfaction

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN LISPRO;

ADULT; ARTICLE; BLOOD GLUCOSE VARIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LABILITY INDEX; LIPID BLOOD LEVEL; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; PATIENT SATISFACTION; STATISTICS AS TOPIC;

EID: 40049100206     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02365.x     Document Type: Article

References (29)

1. The Diabetes Control Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
2. Pickup JC, Mattok M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with Type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002 324 : 1 6.
3. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy. A meta-analysis. Diabetes Care 2003 26 : 1079 1087.
4. Hoogma RP, Hammond PJ, Gomis R, Kerr D, Bruttomesso D, Bouter KP et al. on behalf of the 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med 2006 23 : 141 147.
5. Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004 20 : 178 188.
6. Retnakaran R, Hochman J, De Vries JH, Hanaire-Broutin H, Heine RJ, Melki V et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004 27 : 2590 2596.
7. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 49 : 2142 2148.
8. Ashwell SG, Amiel SA, Biloust RW, Dashora U, Heller SR, Hepburn DA et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006 23 : 285 292.
9. Lepore G, Dodesini AR, Nosari I, Trevisan R. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as Basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003 26 : 1321 1322.
10. Garg SK, Walker AJ, Hoff HK, D'Souza AO, Gottlieb PA, Chase HP. Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol Ther 2004 6 : 9 15.
11. Harmel AP, Mathur R. Similar A1c outcomes in Type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 27 : 272 273.
12. Doyle (Boland) EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized, prospective trial comparing efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004 27 : 1554 1558.
13. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P et al. for the insulin aspart CSII/MDI comparison study Group. Continuous subcutaneous insulin infusion (CSII) of insulin Aspart versus multiple daily injections of insulin aspart/insulin glargine in Type 1 diabetic patients previously treated with CSII. Diabetes Care 2005 28 : 533 538.
14. Pickup JC, Kidd J, Burmiston S, Yemane N. Determinants of glycaemic control in Type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006 22 : 232 237.
15. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with Type 2 diabetes. JAMA 2006 295 : 1681 1687.
16. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005 54 : 1 7.
17. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001 108 : 635 636.
18. Maran A, Crepaldi C, Tiengo A, Grassi G, Vitali E, Pagano G et al. Continuous subcutaneous glucose monitoring in diabetic patients: a multicenter analysis. Diabetes Care 2002 25 : 347 352.
19. Wentholt IM, Vollebregt MA, Hart AA, Hoekstra JB, DeVries JH. Comparison of a needle-Type and a microdialysis continuous glucose monitor in Type 1 diabetic patients. Diabetes Care 2005 28 : 2871 2876.
20. Nicolucci A, Giorgino R, Cucinotta D, Zoppini G, Muggeo M, Squatrito S et al. Validation of the Italian version of the WHO-WELL-Being questionnaire (WHO_WBQ) and the WHO-Diabetes treatment satisfaction questionnaire (WHO_DTSQ). Diabetes Nutr Metab 2004 17 : 235 243.
21. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 1970 19 : 644 655.
22. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D et al. Assessment of the severity of hypoglycemia and glycemic lability in T1 diabetic subjects undergoing islet transplantation. Diabetes 2004 53 : 955 962.
23. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care 2006 29 : 2433 2438.
24. Senn SJ, Hildebrand H. Cross-over trials, degrees of freedom, the carry-over problem and its dual. Stat Med 1991 10 : 1361 1374.
25. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972 28 : 577 584.
26. Schlichtkrull J, Munch O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 1965 177 : 95 102.
27. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006 295 : 1707 1708.
28. Brownlee M. The pathobiology of diabetes complications: a unifying mechanism. Diabetes 2005 54 : 1615 1625.
29. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in Type 1 diabetes. Diabetes Care 2006 29 : 1486 1490.